Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
200 stopped studies mapped to Prostate Carcinoma and descendants · 97% state a reason
Over the 200 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects…(337) | Phase 2 | terminated | Feb 14, 2018 | Brown University | Lack of enrollment secondary to eligibility criteria | Enrollment / accrual |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | Phase 1 / Phase 2 | terminated | Jan 24, 2019 | University of Oxford | COVID stopped all trials - and ADVANCE could not restart again after the pandemic | COVID-19 / pandemic |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | Phase 2 | terminated | Sep 25, 2019 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Phase 1 | terminated | Feb 5, 2021 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | Phase 1 | terminated | Jun 16, 2021 | Rahul Aggarwal | Slow accrual | Enrollment / accrual |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With… | Phase 2 | terminated | Jan 5, 2022 | Coherus Oncology, Inc. | The study was terminated for strategic reasons, not due to any safety concerns. | Safety / toxicity |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 2 | withdrawn | Jul 10, 2018 | M.D. Anderson Cancer Center | Committee could not find that the regulatory approval are met to re-approve this study. | Other (stated, no rule matched) |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With… | Phase 1 / Phase 2 | terminated | Sep 21, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium -…(WB-LuPSMA) | — | terminated | Jan 26, 2022 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The study was linked to another protocol that is over | Other (stated, no rule matched) |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Feb 16, 2022 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant… | Phase 2 | terminated | Aug 15, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by the IRB due to low accrual, | Enrollment / accrual |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic… | Phase 4 | terminated | Oct 22, 2019 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | Phase 2 | terminated | Jul 6, 2021 | University of Washington | Withdrawal of funding | Funding |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate… | Phase 1 / Phase 2 | terminated | Jun 23, 2023 | Oncternal Therapeutics, Inc | Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical… | Other (stated, no rule matched) |
| NCT06016504 | Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients… | N/A | terminated | Aug 29, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Dec 14, 2021 | University of California, San Diego | Oncternal closing clinical trial operations. | Other (stated, no rule matched) |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | Phase 1 / Phase 2 | terminated | Jun 6, 2017 | Institute of Cancer Research, United Kingdom | Discontinuation of production of IMP | Other (stated, no rule matched) |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or… | Phase 1 | terminated | Jan 11, 2023 | University of Chicago | Terminated by the PI | Other (stated, no rule matched) |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | Phase 1 / Phase 2 | withdrawn | Mar 26, 2024 | Baptist Health South Florida | Funding for the study was withdrawn. | Funding |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | terminated | Feb 22, 2019 | Hinova Pharmaceuticals USA, Inc. | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | Enrollment / accrual |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in… | Phase 1 | terminated | Nov 16, 2020 | Swiss Cancer Institute | SAKK decided to premature terminate this trial as additional follow-up visits do not further… | Efficacy / futility |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Nov 12, 2019 | Barbara Ann Karmanos Cancer Institute | The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA… | Safety / toxicity |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Phase 2 | terminated | Dec 10, 2018 | Jodi Layton, MD | Early signs of progression and learned experience that the assumed time period between psa… | Other (stated, no rule matched) |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced… | Phase 2 | terminated | Oct 1, 2018 | Effector Therapeutics | Terminated early due to a lack of efficacy. | Efficacy / futility |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP… | Phase 1 | withdrawn | Apr 11, 2023 | National Cancer Institute (NCI) | No subjects enrolled in the study | Enrollment / accrual |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | Phase 1 / Phase 2 | terminated | Jul 7, 2020 | Institute of Cancer Research, United Kingdom | Funder decided that response outcomes to date did not support continuation of the study. | Other (stated, no rule matched) |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for… | Phase 2 | withdrawn | Jul 6, 2022 | National Cancer Institute (NCI) | Closed by study team, no subjects enrolled. | Enrollment / accrual |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | Phase 2 | withdrawn | Sep 5, 2021 | M.D. Anderson Cancer Center | Per PI no participants enrolled | Enrollment / accrual |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic… | Phase 2 | terminated | Mar 5, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate…(HIIT PCa) | N/A | withdrawn | Dec 14, 2021 | The University of Texas Health Science Center at San Antonio | PI left the institution, no subjects were enrolled | Investigator |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One…(VERACITY) | Phase 3 | terminated | Apr 14, 2021 | Veru Inc. | Administrative reasons | Other (stated, no rule matched) |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Jan 6, 2023 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Nov 18, 2021 | Immunic AG | Lack of Efficacy | Efficacy / futility |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of… | — | withdrawn | Apr 11, 2018 | HKGepitherapeutics | No participants enrolled, leading to insufficient patient numbers to initiate the clinical trial. | Enrollment / accrual |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate…(REPAIR) | Phase 1 | suspended | Jun 21, 2022 | Peter MacCallum Cancer Centre, Australia | Enrolment suspended to further assess supplementary non-clinical study data. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in… | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The sponsor voluntarily terminated the study | Other (stated, no rule matched) |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron… | Phase 2 | terminated | Aug 28, 2018 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double… | Phase 2 | terminated | Jun 26, 2019 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic… | Phase 1 / Phase 2 | terminated | Nov 23, 2018 | Veru Inc. | Administrative decision | Other (stated, no rule matched) |
| NCT05301062 | A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well…(CREDIT) | — | terminated | Mar 29, 2022 | Bayer | Due to the changes of standard of care, the slow recruitment of participants, and the similar… | Safety / toxicity |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 25, 2010 | University of Nebraska | study sponsors withdrew support for the study drug. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 8, 2025source: clinicaltrials